文献速递消化道肿瘤放疗

局部晚期直肠癌改变分割短程放疗的回顾性研究

Altered fractionation short-course radiotherapy for stage II-III rectal cancer: a retrospective study.
PubMed 文献 · Radiat Oncol · 2020-05-14

该单中心回顾性研究纳入271例II-III期直肠癌患者,评估新辅助改变分割短程放疗(25 Gy/10次,2.5 Gy每日两次)的长期结局。中位随访101个月,局部复发率4.4%,5年和10年总生存率分别为73%和55.5%,多数无永久造口患者功能结局良好。

要点

  • 25 Gy/10次改变分割短程放疗方案可行,局部复发率低(4.4%)。
  • 5年和10年总生存率分别为73%和55.5%。
  • 79%无永久造口患者无LARS,仅12%报告严重LARS。

核心结论

  • 该改变分割短程放疗方案可行,局部复发率低,多数患者功能结局良好。

研究设计与样本

  • 单中心回顾性研究,纳入271例连续II-III期直肠癌患者,中位随访101个月。

主要发现

  • 12例(4.4%)出现局部复发,中位复发时间28个月。
  • 5年和10年总生存率分别为73%和55.5%,无病生存率分别为65.5%和51%。
  • 无永久造口患者中79%无LARS(0-20分),9%为21-29分,12%为严重LARS(30-42分)。

关键数值与推荐

  • 放疗方案为25 Gy分10次,每次2.5 Gy,每日两次。
  • 放疗至手术中位间隔5天。

临床怎么用

  • 该方案可作为II-III期直肠癌新辅助放疗的可选策略,需关注长期功能结局。

局限性

  • 回顾性单中心设计,功能结局仅通过电话访谈获取。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: To report the long-term outcomes of neoadjuvant altered fractionation short-course radiotherapy in 271 consecutive patients with stage II-III rectal cancer. PATIENTS AND METHODS: This was a retrospective single institution study with median follow-up of 101 months (8.4 years). Patients who were alive at the time of analysis in 2018 were contacted to obtain functional outcome data (phone interview). Radiotherapy consisted of 25 Gy in 10 fractions of 2.5 Gy administered twice daily. Median time interval to surgery was 5 days. RESULTS: Local relapse was observed in 12 patients (4.4%) after a median of 28 months. Overall survival after 5 and 10 years was 73 and 55.5%, respectively (corresponding disease-free survival 65.5 and 51%). Of all patients without permanent stoma, 79% reported no low anterior resection syndrome (LARS; 0-20 points), 9% reported LARS with 21-29 points and 12% serious LARS (30-42 points). CONCLUSION: The present radiotherapy regimen was feasible and resulted in low rates of local relapse. Most patients reported good functional outcomes.

来源:Radiat Oncol,查看原文。版权归原作者所有。

引用

  1. Geinitz H, Nieder C, Kocik L, et al. Altered fractionation short-course radiotherapy for stage II-III rectal cancer: a retrospective study. Radiat Oncol. 2020. PMID: 32410643. doi:10.1186/s13014-020-01566-8

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。